Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer

Expert Opinion on Therapeutic Targets
Pieter H AnborghAnn F Chambers

Abstract

Effective targeted therapies for patients with triple-negative breast cancer (TNBC) present an unmet clinical need. There is evidence that TNBCs often have increased expression of the epidermal growth factor receptor (EGFR) and of osteopontin (OPN). OPN-mediated signaling can activate EGFR-dependent signaling pathways. Here, we assessed OPN as a potential predictive biomarker for response to anti-EGFR therapy in TNBC. Using two different TNBC cell lines, MDA-MB-468 and MDA-MB-231, we investigated the impact of stable expression of OPN on efficacy of the EGFR inhibitor erlotinib in vitro. We observed that breast cancer cells engineered to overexpress OPN are more sensitive to growth inhibition by erlotinib than control cells. The level of response was related to the level of OPN expression, possibly due to increased phosphorylation status of EGFR Tyr1068. These results indicate that OPN expression levels are related to sensitivity of TNBC cells to growth inhibition by erlotinib. OPN thus is a promising predictive biomarker for anti-EGFR therapy in breast cancer.

References

Oct 7, 1998·International Journal of Cancer. Journal International Du Cancer·A B TuckA F Chambers
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Jun 25, 2003·Expert Review of Anticancer Therapy·Anca M BulgaruRoman Perez-Soler
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vivien H C BramwellAnn F Chambers
Jul 4, 2006·The American Journal of Pathology·Alison L AllanAlan B Tuck
Aug 3, 2007·Molecular Cancer Therapeutics·Fumiyuki YamasakiNaoto T Ueno
May 23, 2008·Breast Cancer Research and Treatment·Maura N DicklerEric P Winer
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B CorkeryN O'Donovan
Jan 31, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Yanyan LiDuxin Sun
Mar 17, 2009·Biochemical and Biophysical Research Communications·Sergey V IvanovHarvey I Pass
Apr 26, 2011·Journal of Cell Communication and Signaling·Pieter H AnborghAnn F Chambers
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Apr 21, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma
Mar 6, 2013·Nature Reviews. Clinical Oncology·Dimitrios ZardavasMartine Piccart
May 3, 2013·Frontiers in Pharmacology·Rolando PerezErnesto Moreno
Jun 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaAhmad Awada
Mar 25, 2014·Matrix Biology : Journal of the International Society for Matrix Biology·Lalita A Shevde, Rajeev S Samant
Jun 6, 2014·Expert Opinion on Therapeutic Targets·Monalisa BandopadhyayGopal C Kundu
Aug 6, 2014·Journal of Surgical Oncology·Julie E LangDebasish Tripathy
Mar 24, 2015·Molecular and Clinical Oncology·Ying-Yi XuYu-Qiang Chen
May 15, 2015·American Journal of Clinical Pathology·Fernando Ortiz-MartínezGloria Peiró
Apr 26, 2017·International Journal of Molecular Medicine·Chengcheng HaoWen G Jiang
Aug 16, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fausto PetrelliSandro Barni
Sep 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma

❮ Previous
Next ❯

Citations

Oct 2, 2019·Laboratory Investigation; a Journal of Technical Methods and Pathology·Milica KrsticAlan B Tuck
Nov 2, 2019·Biomarkers in Medicine·Xiaofeng DaiPeihua Lu
Aug 7, 2019·Cells·Anne-Sophie LamortGeorgios T Stathopoulos
Jan 28, 2021·Sensors·Kamila MaleckaElena E Ferapontova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.